FCCC LOGO Faculty Publications
Ozols RF
Chemotherapy for advanced epithelial ovarian cancer
Hematology/Oncology Clinics of North America. 1992 ;6(4) :879-894
Back to previous list
Abstract
In the past decade there have been significant improvements in chemotherapy for advanced ovarian cancer. Platinum-based chemotherapy has improved response rates and, to a lesser degree, prolonged survival. Taxol and its combination with platinum drugs holds the promise for even further improvements in survival. Clinical trials are evaluating issues such as dose- intensity, new combinations, and drug resistance.
Notes
08898588 (ISSN) Cited By: 14; Export Date: 31 May 2006; Source: Scopus CODEN: HCNAE Language of Original Document: English Correspondence Address: Ozols, R.F.; Department of Medical Oncology; Fox Chase Cancer Center; 7701 Burholme Avenue Philadelphia, PA 19111, United States Chemicals/CAS: altretamine, 15468-34-5, 2975-00-0, 645-05-6; carboplatin, 41575-94-4; cisplatin, 15663-27-1, 26035-31-4, 96081-74-2; cyclophosphamide, 50-18-0; doxorubicin, 23214-92-8, 25316-40-9; ifosfamide, 3778-73-2, Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols